Hepion Pharmaceuticals, Inc. (HEPA)

Hepion Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	8.85	9.62	10.35	10.01	8.15	4.59
Research & Development	28.38	35.64	33.27	20.4	12	3.18
Other Operating Expenses	3.19	3.19	1.87	0	0	0
Operating Expenses	40.42	48.45	45.49	30.4	20.15	7.77
Operating Income	-40.42	-48.45	-45.49	-30.4	-20.15	-7.77
Interest Expense / Income	0.01	0.01	0.01	0.01	0.03	0.55
Other Expense / Income	1.47	0.88	-0.41	2.31	0.15	-0.38
Pretax Income	-41.9	-49.34	-45.08	-32.72	-20.32	-7.95
Income Tax	-3.38	-0.41	-2.88	0	0.03	-0.91
Net Income	-38.52	-48.93	-42.2	-32.72	-20.35	-7.04
Preferred Dividends	0	0	3.14	0	0.01	5.44
Net Income Common	-38.52	-48.93	-45.34	-32.72	-20.36	-12.48
Shares Outstanding (Basic)	5	4	4	4	0	0
Shares Outstanding (Diluted)	5	4	4	4	0	0
Shares Change	33.09%	4.18%	8.45%	626.31%	373.65%	1011.18%
EPS (Basic)	-9.40	-12.32	-11.90	-9.40	-42.00	-122.20
EPS (Diluted)	-9.40	-12.32	-11.90	-9.40	-42.00	-122.20
Free Cash Flow	-36.31	-40.9	-34.98	-31.35	-16.25	-7.62
Free Cash Flow Per Share	-7.16	-10.30	-9.18	-8.92	-33.58	-74.55
EBITDA	-41.81	-49.26	-45	-32.63	-20.26	-7.36
Depreciation & Amortization	0.08	0.07	0.08	0.09	0.03	0.03
EBIT	-41.89	-49.33	-45.07	-32.71	-20.29	-7.39

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).